PUBLIC COMPANY
saveAMO Pharma Ltd
founded 2015 · Leeds, England, GBupdated 1mo ago
AMO Pharma is a privately held clinical-stage biopharmaceutical company developing therapies for rare genetic neurodevelopmental and neuromuscular disorders. Its lead asset is AMO-02 (tideglusib), a GSK-3 inhibitor in development for congenital and childhood-onset myotonic dystrophy type 1, alongside additional programs in Phelan-McDermid and Rett syndromes.
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
comments(0)
5-min edit window · permanent after that